Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 27.5% gain over the past six months, beating the S&P 500 by 16.2 percentage points.

IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.

DexCom stock has gained 33.4% year to date, yet the valuation picture is mixed, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to meaningful upside while the broader checks lean less generous. For investors, the question is how to weigh a DCF signal that suggests the shares trade at a discount against a low overall value score. Year to date, DexCom is up 33.4%, which puts more pressure on the current price to be supported by future cash flows. Expectations...

DexCom stock reacts to recent performance and fundamentals DexCom (DXCM) has attracted investor attention after a recent share price move, with the stock closing at US$89.75. The company’s returns over the past month and past 3 months now stand out against its longer term record. See our latest analysis for DexCom. Short term momentum in DexCom has been strong, with the 30 day share price return of 17.09% and the 90 day share price return of 34.06% contrasting with a more modest 1 year total...

DexCom’s latest analyst work shows a modest lift in the modelled fair value, with the price target figure moving from US$91.64 to US$94.12. This adjustment sits alongside mixed analyst commentary that balances positive Q2 2026 execution, new clinical data and guidance updates, and ongoing questions about valuation and sector sentiment. As you read on, you will see how these moving parts shape the current story around DexCom and how to keep track of future shifts in the narrative. Stay updated...

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.

DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.

DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.

DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuation, competition and litigation raise the bar.

Revenue hit $1.31 billion with strong international growth and margin expansion.

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DexCom’s fair value estimate has shifted from US$85.24 to US$91.64, marking a moderate uplift in the price target range currently referenced for the stock. This move lines up with recent analyst commentary, where many firms are reaffirming or raising targets, while a smaller group trims expectations on valuation concerns and growth assumptions. As you read on, you will see how these price target adjustments fit into the broader DexCom narrative and what to watch to stay aligned with the...

In late July 2026, DexCom reported second-quarter results showing higher sales and earnings than a year earlier and raised its full-year 2026 revenue outlook to US$5.18 billion–US$5.25 billion, implying around 11–13% growth. Beyond the headline numbers, DexCom highlighted progress in expanding access for type 2 diabetes patients not using insulin and advancing next-generation sensors, underlining its push into broader metabolic health monitoring. We’ll now look at how DexCom’s raised 2026...

Medical device company DexCom (NASDAQ:DXCM) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.31 billion. The company expects the full year’s revenue to be around $5.22 billion, close to analysts’ estimates. Its non-GAAP profit of $0.70 per share was 15.1% above analysts’ consensus estimates.

DXCM's Q2 earnings and revenues beat estimates as global demand, broader access and margin expansion fuel stronger 2026 guidance.

Following the release of its Q2 results on 30 July, Dexcom's company’s shares on the Nasdaq rose over 8% to $81.04 at market open on 31 July.

Shares of medical device company DexCom (NASDAQ:DXCM) jumped 10.9% in the morning session after the company reported strong second-quarter results and slightly raised its full-year financial outlook.

DexCom Inc (DXCM) delivered 13% revenue growth and raised full-year guidance, driven by strong international performance and improved margins.

Revenue hit $1.31 billion with strong international growth and margin expansion.

Moby summary of DexCom, Inc.'s Q2 2026 earnings call

DexCom (NASDAQ:DXCM) reported second-quarter 2026 revenue growth of 13% from a year earlier, supported by continued demand for continuous glucose monitoring systems, expanding reimbursement access and share gains across several patient groups and markets. Worldwide revenue totaled $1.31 billion, co

DexCom (DXCM) delivered earnings and revenue surprises of +14.75% and +1.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q2 CY2026, with sales up 13.1% year on year to $1.31 billion. The company expects the full year’s revenue to be around $5.22 billion, close to analysts’ estimates. Its non-GAAP profit of $0.70 per share was 15.1% above analysts’ consensus estimates.

They may profit from the rapidly growing GLP-1 market in very different ways.

Align Technology will add three new independent directors to its board and launch a review of its operations ‌following talks with activist investor Elliott Investment Management, the company said ‌on Wednesday. The three new board ​members, who have not yet been named, will be chosen for their expertise in healthcare technology, medical devices, global operations, and scaling high-growth businesses. Elliott, one of Wall Street's most prominent activist investors, has increasingly turned its attention to ‌healthcare companies over the past ⁠year, often pushing for board representation and strategic reviews to boost performance.

DexCom (DXCM) has been back on radar after its recent share price move, with the stock closing at $74.85. Investors are weighing that price against the company’s current fundamentals and recent trading performance. See our latest analysis for DexCom. The recent 1 day share price return of 2.02% and 90 day share price return of 30.04% suggest momentum has been building for DexCom, even though the 1 year total shareholder return declined 16.23%. If DexCom’s move has you thinking about other...

Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls

SYK heads into Q2 with robotic surgery momentum, deferred revenue recovery and strong procedure demand as investors watch for earnings and margin trends.

DXCM's Q2 results may reflect strong G7 15 Day adoption, broader reimbursement, and expanding CGM demand as investors watch for continued double-digit revenue growth.

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is how DexCom (DXCM) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Stock Market Today: The Nasdaq composite dropped Thursday as Sandisk and SK Hynix plunged. TSMC sold off on earnings.

Wall Street still prices Abbott like a slow-and-steady dividend stalwart, but a pair of massive strategic moves beneath the surface suggests that framing may be costing investors a significant opportunity.

DexCom's G7 15 Day wins Health Canada authorization, offering longer wear, high accuracy and smart features for adults with diabetes.

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.